Loading...

Carlie Tanner, MD, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentNeurology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ross GW, Abbott RD, Petrovitch H, Duda JE, Tanner CM, Zarow C, Uyehara-Lock JH, Masaki KH, Launer LJ, Studabaker WB, White LR. Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology. Mov Disord. 2018 Dec 30. PMID: 30597605.
      View in: PubMed
    2. Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018 Dec; 5(12):1460-1477. PMID: 30564614.
      View in: PubMed
    3. Checkoway H, Ilango S, Li W, Ray RM, Tanner CM, Hu SC, Wang X, Nielsen S, Gao DL, Thomas DB. Occupational exposures and parkinsonism among Shanghai women textile workers. Am J Ind Med. 2018 Sep 09. PMID: 30198067.
      View in: PubMed
    4. Brown EG, Goldman SM, Tanner CM. Mendel and urate: Acid test or random noise? Parkinsonism Relat Disord. 2018 Aug 07. PMID: 30100365.
      View in: PubMed
    5. Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C. Reproducibility of data-driven Parkinson's disease subtypes for clinical research. Parkinsonism Relat Disord. 2018 Nov; 56:102-106. PMID: 30056038.
      View in: PubMed
    6. Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K. Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Mov Disord. 2018 Mar 23. PMID: 29572948.
      View in: PubMed
    7. Hassan A, Dorsey ER, Goetz CG, Bloem BR, Guttman M, Tanner CM, Mari Z, Pantelyat A, Galifianakis NB, Bajwa JA, Gatto EM, Cubo E. Telemedicine Use for Movement Disorders: A Global Survey. Telemed J E Health. 2018 Mar 22. PMID: 29565764.
      View in: PubMed
    8. Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102. Mov Disord Clin Pract. 2018 Mar-Apr; 5(2):183-190. PMID: 29780852.
      View in: PubMed
    9. Tanner C, Marder K, Eberly S, Biglan K, Oakes D, Shoulson I. Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease. Mov Disord. 2018 Mar; 33(3):472-478. PMID: 29297592.
      View in: PubMed
    10. Brown EG, Tanner CM. Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind. JAMA Neurol. 2017 Dec 01; 74(12):1398-1400. PMID: 28973080.
      View in: PubMed
    11. Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. J Neurol Neurosurg Psychiatry. 2018 Jan; 89(1):78-88. PMID: 28986467.
      View in: PubMed
    12. Ritz BR, Chatterjee N, Garcia-Closas M, Gauderman WJ, Pierce BL, Kraft P, Tanner CM, Mechanic LE, McAllister K. Lessons Learned From Past Gene-Environment Interaction Successes. Am J Epidemiol. 2017 Oct 01; 186(7):778-786. PMID: 28978190.
      View in: PubMed
    13. Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord. 2017 Dec; 32(12):1701-1709. PMID: 28833562.
      View in: PubMed
    14. Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017 Sep 12; 89(11):1152-1161. PMID: 28814455.
      View in: PubMed
    15. Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol. 2017 Aug 01; 74(8):941-949. PMID: 28604926.
      View in: PubMed
    16. Korn RE, Wagle Shukla A, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, Dorsey ER, Biglan KM, Kang G, Kanchana S, Rodriguez R, Tanner CM, Galifianakis NB. Virtual visits for Parkinson disease: A multicenter noncontrolled cohort. Neurol Clin Pract. 2017 08; 7(4):283-295. PMID: 28840919.
      View in: PubMed
    17. Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 2017 08; 16(8):620-629. PMID: 28629879.
      View in: PubMed
    18. Hayete B, Wuest D, Laramie J, McDonagh P, Church B, Eberly S, Lang A, Marek K, Runge K, Shoulson I, Singleton A, Tanner C, Khalil I, Verma A, Ravina B. A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. PLoS One. 2017; 12(6):e0178982. PMID: 28604798.
      View in: PubMed
    19. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23; 3:17013. PMID: 28332488.
      View in: PubMed
    20. Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017 03; 32(3):319-324. PMID: 28233927.
      View in: PubMed
    21. Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T. Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci. 2017 Apr 15; 375:355-359. PMID: 28320167.
      View in: PubMed
    22. Visanji NP, Bhudhikanok GS, Mestre TA, Ghate T, Udupa K, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kim S, Azhu Valappil R, Kausar F, Rogaeva E, William Langston J, Tanner CM, Schüle B, Lang AE, Goldman SM, Marras C. Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. Mov Disord. 2017 04; 32(4):610-614. PMID: 28071824.
      View in: PubMed
    23. Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis. 2017; 7(3):511-522. PMID: 28777755.
      View in: PubMed
    24. Hopfner F, Haubenberger D, Galpern WR, Gwinn K, Van't Veer A, White S, Bhatia K, Adler CH, Eidelberg D, Ondo W, Stebbins GT, Tanner CM, Helmich RC, Lenz FA, Sillitoe RV, Vaillancourt D, Vitek JL, Louis ED, Shill HA, Frosch MP, Foroud T, Kuhlenbäumer G, Singleton A, Testa CM, Hallett M, Elble R, Deuschl G. Knowledge gaps and research recommendations for essential tremor. Parkinsonism Relat Disord. 2016 Dec; 33:27-35. PMID: 27769649.
      View in: PubMed
    25. LaHue SC, Comella CL, Tanner CM. The best medicine? The influence of physical activity and inactivity on Parkinson's disease. Mov Disord. 2016 10; 31(10):1444-1454. PMID: 27477046.
      View in: PubMed
    26. Mehta SH, Tanner CM. Role of Neuroinflammation in Parkinson Disease: The Enigma Continues. Mayo Clin Proc. 2016 10; 91(10):1328-1330. PMID: 27712631.
      View in: PubMed
    27. Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K. Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. Ann Clin Transl Neurol. 2016 Jul; 3(7):482-94. PMID: 27386498; PMCID: PMC4931714.
    28. Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord. 2016 07; 28:62-7. PMID: 27132498.
      View in: PubMed
    29. Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol. 2016 Jun; 131(6):935-49. PMID: 27021906.
      View in: PubMed
    30. Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 07; 22(7):590-8. PMID: 26886406.
      View in: PubMed
    31. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10. PMID: 26569098.
      View in: PubMed
    32. Kurlan R, Ravina B, Eberly S, Lang AE, Tanner CM, Marek K, Marder K, Beck J, Elliott R, Oakes D, Shoulson I. Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. Mov Disord Clin Pract. 2016 Jan-Feb; 3(1):53-58. PMID: 30363507.
      View in: PubMed
    33. Abbott RD, Ross GW, Petrovitch H, Masaki KH, Launer LJ, Nelson JS, White LR, Tanner CM. Midlife milk consumption and substantia nigra neuron density at death. Neurology. 2016 Feb 09; 86(6):512-9. PMID: 26658906; PMCID: PMC4753730 [Available on 02/09/17].
    34. Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol. 2015 Sep-Oct; 38(5):163-9. PMID: 26366971; PMCID: PMC4573899.
    35. Chen H, Ding D, Wang J, Zhao Q, Meng H, Li H, Gao YT, Shu XO, Tanner CM, Hong Z, Yang G. Parkinson's disease research in a prospective cohort in China. Parkinsonism Relat Disord. 2015 Oct; 21(10):1200-4. PMID: 26318964.
      View in: PubMed
    36. Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, Mendick S, Seibyl J, Simuni T, Zhang Y, Jankovic J, Hunter C, Tanner CM, Rees L, Factor S, Berg D, Wurster I, Gauss K, Sprenger F, Seppi K, Poewe W, Mollenhauer B, Knake S, Mari Z, McCoy A, Ranola M, Marek K. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015 Dec; 30(14):1885-92. PMID: 26260437.
      View in: PubMed
    37. Van Den Eeden SK, Albers KB, Davidson JE, Kushida CA, Leimpeter AD, Nelson LM, Popat R, Tanner CM, Bibeau K, Quesenberry CP. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California. Sleep. 2015 Jul 01; 38(7):1009-15. PMID: 26083613; PMCID: PMC4481004.
    38. Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9. PMID: 26025783; PMCID: PMC4472464.
    39. Kirrane EF, Bowman C, Davis JA, Hoppin JA, Blair A, Chen H, Patel MM, Sandler DP, Tanner CM, Vinikoor-Imler L, Ward MH, Luben TJ, Kamel F. Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study. J Occup Environ Med. 2015 May; 57(5):509-17. PMID: 25951420.
      View in: PubMed
    40. Gardner RC, Burke JF, Nettiksimmons J, Goldman S, Tanner CM, Yaffe K. Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol. 2015 Jun; 77(6):987-95. PMID: 25726936; PMCID: PMC4447556.
    41. Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Dürr A, Brice A, Takashima H, Kikuchi A, Aoki M, Ishiura H, Yasuda T, Date H, Ahsan B, Iwata A, Goto J, Ichikawa Y, Nakahara Y, Momose Y, Takahashi Y, Hara K, Kakita A, Yamada M, Takahashi H, Onodera O, Nishizawa M, Watanabe H, Ito M, Sobue G, Ishikawa K, Mizusawa H, Kanai K, Hattori T, Kuwabara S, Arai K, Koyano S, Kuroiwa Y, Hasegawa K, Yuasa T, Yasui K, Nakashima K, Ito H, Izumi Y, Kaji R, Kato T, Kusunoki S, Osaki Y, Horiuchi M, Kondo T, Murayama S, Hattori N, Yamamoto M, Murata M, Satake W, Toda T, Filla A, Klockgether T, Wüllner U, Nicholson G, Gilman S, Tanner CM, Kukull WA, Stern MB, Lee VM, Trojanowski JQ, Masliah E, Low PA, Sandroni P, Ozelius LJ, Foroud T, Tsuji S. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015 Apr; 2(4):417-26. PMID: 25909086; PMCID: PMC4402086.
    42. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. PMID: 25668262; PMCID: PMC4349346.
    43. Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord. 2015 May; 30(6):788-95. PMID: 25650051; PMCID: PMC5024015.
    44. Tanner CM, Comella CL. When brawn benefits brain: physical activity and Parkinson's disease risk. Brain. 2015 Feb; 138(Pt 2):238-9. PMID: 25627233; PMCID: PMC4394643.
    45. Furlong M, Tanner CM, Goldman SM, Bhudhikanok GS, Blair A, Chade A, Comyns K, Hoppin JA, Kasten M, Korell M, Langston JW, Marras C, Meng C, Richards M, Ross GW, Umbach DM, Sandler DP, Kamel F. Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. Environ Int. 2015 Feb; 75:144-50. PMID: 25461423.
      View in: PubMed
    46. Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS. The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. Mov Disord. 2015 Feb; 30(2):278-83. PMID: 25393808; PMCID: PMC4318772.
    47. Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol. 2014 Dec; 76(6):862-8. PMID: 25257975; PMCID: PMC4245314.
    48. Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K. Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. Genet Med. 2014 Aug; 16(8):644-5. PMID: 25093570.
      View in: PubMed
    49. Tanner CM, Goldman SM, Ross GW, Grate SJ. The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S213-25. PMID: 24924672.
      View in: PubMed
    50. Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Dorsey ER, Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson JR. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014 Jun; 29(7):871-83. PMID: 24838316.
      View in: PubMed
    51. Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Sandler DP, Langston JW, Tanner CM. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 Aug; 29(9):1171-80. PMID: 24838182.
      View in: PubMed
    52. Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, DiEuliis D, Fahn S, Elliott RA, Shoulson I. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9. PMID: 24515275.
      View in: PubMed
    53. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol. 2014 Jan; 71(1):62-7. PMID: 24190026; PMCID: PMC3947132.
    54. Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013 Nov; 70(11):1382-8. PMID: 24000094; PMCID: PMC4040231.
    55. Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6. PMID: 24123383.
      View in: PubMed
    56. Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster Ross G, William Langston J, Sandler DP, Tanner CM. Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat Disord. 2014 Jan; 20(1):82-7. PMID: 24120951.
      View in: PubMed
    57. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM. Association of cerebrospinal fluid ß-amyloid 1-42, T-tau, P-tau181, and a-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013 Oct; 70(10):1277-87. PMID: 23979011.
      View in: PubMed
    58. Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J. Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications. Environ Health Perspect. 2013 Nov-Dec; 121(11-12):1245-52. PMID: 23933572; PMCID: PMC3855519.
    59. Tanner CM. Alpha-synuclein: one key opens many locks. Mov Disord. 2013 Aug; 28(9):1176-8. PMID: 23925937.
      View in: PubMed
    60. Tanner CM. A second honeymoon for Parkinson's disease? N Engl J Med. 2013 Feb 14; 368(7):675-6. PMID: 23406033.
      View in: PubMed
    61. Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6. PMID: 23390076.
      View in: PubMed
    62. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3. PMID: 23339054; PMCID: PMC3608707.
    63. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis. 2013 Jan 01; 3(3):231-9. PMID: 24018336; PMCID: PMC4318242.
    64. Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM. Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord. 2012 Nov; 27(13):1652-8. PMID: 23045187.
      View in: PubMed
    65. Ross GW, Duda JE, Abbott RD, Pellizzari E, Petrovitch H, Miller DB, O'Callaghan JP, Tanner CM, Noorigian JV, Masaki K, Launer L, White LR. Brain organochlorines and Lewy pathology: the Honolulu-Asia Aging Study. Mov Disord. 2012 Sep 15; 27(11):1418-24. PMID: 22976848; PMCID: PMC3474594.
    66. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord. 2012 Sep 15; 27(11):1392-7. PMID: 22976926.
      View in: PubMed
    67. Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P. Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat Disord. 2012 Sep; 18(8):958-63. PMID: 22658533.
      View in: PubMed
    68. Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman SA, Kamel F, Nelson LM, Topol B, Van den Eeden SK, Tanner CM, Cudkowicz ME, Grasso DL, Lawson R, Muralidhar S, Oddone EZ, Schmidt S, Hauser MA. A high-density genome-wide association screen of sporadic ALS in US veterans. PLoS One. 2012; 7(3):e32768. PMID: 22470424.
      View in: PubMed
    69. Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012 Mar; 71(3):370-84. PMID: 22451204.
      View in: PubMed
    70. Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8. PMID: 22275250.
      View in: PubMed
    71. Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S199-202. PMID: 22166434.
      View in: PubMed
    72. Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM. Solvent exposures and Parkinson disease risk in twins. Ann Neurol. 2012 Jun; 71(6):776-84. PMID: 22083847; PMCID: PMC3366287.
    73. Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011 Jun; 7(6):e1002141. PMID: 21738487; PMCID: PMC3121750.
    74. Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar; 26(4):608-13. PMID: 21287602.
      View in: PubMed
    75. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 2011 Jun; 119(6):866-72. PMID: 21269927; PMCID: PMC3114824.
    76. Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc. 2011 Jan; 17(1):91-100. PMID: 21092386; PMCID: PMC3366462.
    77. Shino MY, McGuire V, Van Den Eeden SK, Tanner CM, Popat R, Leimpeter A, Bernstein AL, Nelson LM. Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study. Mov Disord. 2010 Nov 15; 25(15):2587-94. PMID: 20842689; PMCID: PMC2978761.
    78. Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, Langston JW. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord. 2010 Oct 30; 25(14):2296-303. PMID: 20976736.
      View in: PubMed
    79. Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM. Comorbid cancer in Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1809-17. PMID: 20669266.
      View in: PubMed
    80. Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8. PMID: 20669311.
      View in: PubMed
    81. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep; 67(9):1116-22. PMID: 20837857; PMCID: PMC3329730.
    82. Abbott RD, Ross GW, Tanner CM, Andersen JK, Masaki KH, Rodriguez BL, White LR, Petrovitch H. Late-life hemoglobin and the incidence of Parkinson's disease. Neurobiol Aging. 2012 May; 33(5):914-20. PMID: 20709430; PMCID: PMC3006667.
    83. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15; 25(9):1190-4. PMID: 20629138.
      View in: PubMed
    84. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol. 2010 Jun; 67(6):731-8. PMID: 20558392; PMCID: PMC3329757.
    85. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010 Aug; 32(7):775-9. PMID: 20182943; PMCID: PMC2911493.
    86. Popat RA, Van Den Eeden SK, Tanner CM, Kushida CA, Rama AN, Black JE, Bernstein A, Kasten M, Chade A, Leimpeter A, Cassidy J, McGuire V, Nelson LM. Reliability and validity of two self-administered questionnaires for screening restless legs syndrome in population-based studies. Sleep Med. 2010 Feb; 11(2):154-60. PMID: 20089446.
      View in: PubMed
    87. Tanner CM. Advances in environmental epidemiology. Mov Disord. 2010; 25 Suppl 1:S58-62. PMID: 20187243.
      View in: PubMed
    88. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1517-22. PMID: 20008657; PMCID: PMC2837584.
    89. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1460-8. PMID: 19822770; PMCID: PMC2795011.
    90. Lo RY, Tanner CM, Albers KB, Leimpeter AD, Fross RD, Bernstein AL, McGuire V, Quesenberry CP, Nelson LM, Van Den Eeden SK. Clinical features in early Parkinson disease and survival. Arch Neurol. 2009 Nov; 66(11):1353-8. PMID: 19901166.
      View in: PubMed
    91. Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90. PMID: 19691116.
      View in: PubMed
    92. Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13. PMID: 19752299.
      View in: PubMed
    93. Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P. Health related quality of life in early Parkinson's disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord. 2009 Dec; 15(10):767-71. PMID: 19553154.
      View in: PubMed
    94. Petrovitch H, Abbott RD, Ross GW, Nelson J, Masaki KH, Tanner CM, Launer LJ, White LR. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord. 2009 Feb 15; 24(3):371-6. PMID: 19006191; PMCID: PMC3272050.
    95. Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2009 Feb 10; 72(6):578-9. PMID: 19204275.
      View in: PubMed
    96. Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008 Oct; 139(4):495-505. PMID: 18922334.
      View in: PubMed
    97. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord. 2008 Sep 15; 23(12):1641-52. PMID: 18683238; PMCID: PMC4430096.
    98. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, Logroscino G, Nelson L, Ravina B, Rocca W, Ross GW, Schettler T, Schwarzschild M, Scott B, Seegal R, Singleton A, Steenland K, Tanner CM, Van Den Eeden S, Weisskopf M. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009 Jan; 117(1):117-21. PMID: 19165397; PMCID: PMC2627854.
    99. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord. 2008 Apr 15; 23(5):653-9; quiz 776. PMID: 18076084.
      View in: PubMed
    100. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008 Feb; 63(2):167-73. PMID: 18067173.
      View in: PubMed
    101. May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7. PMID: 17914727.
      View in: PubMed
    102. Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007 Aug 15; 22(11):1581-6. PMID: 17523195.
      View in: PubMed
    103. Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, McGuire V, Nelson LM. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007 Jun; 8(3):157-63. PMID: 17538777.
      View in: PubMed
    104. Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007 Mar 15; 22(4):546-9. PMID: 17230458.
      View in: PubMed
    105. Kasten M, Chade A, Tanner CM. Epidemiology of Parkinson's disease. Handb Clin Neurol. 2007; 83:129-51. PMID: 18808913.
      View in: PubMed
    106. Langston JW, Tanner CM, Schüle B. Parkin gene variations and parkinsonism: association does not imply causation. Ann Neurol. 2007 Jan; 61(1):4-6. PMID: 17262853.
      View in: PubMed
    107. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006 Dec; 21(12):2062-7. PMID: 16991138.
      View in: PubMed
    108. Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Krüger R, Marder KS, Mayeux RP, Mellick GD, Nutt JG, Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP, Dehem M, Montimurro JS, Southwick A, Myers RM, Trikalinos TA. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol. 2006 Nov; 5(11):917-23. PMID: 17052658; PMCID: PMC3636768.
    109. Popat RA, Van Den Eeden SK, Tanner CM, Bernstein AL, Bloch DA, Leimpeter A, McGuire V, Nelson LM. Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology. 2006; 27(3):117-21. PMID: 16946622.
      View in: PubMed
    110. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins. Ann Neurol. 2006 Jul; 60(1):65-72. PMID: 16718702.
      View in: PubMed
    111. Glatt C, Almonte M, Taylor T, Edwards RH, Freimer N, Tanner C. Structural variants in the vesicular monoamine transporter do not contribute to sporadic Parkinson's disease. Mov Disord. 2006 Mar; 21(3):426-7. PMID: 16450345.
      View in: PubMed
    112. Tröster AI, Pahwa R, Fields JA, Tanner CM, Lyons KE. Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation. Parkinsonism Relat Disord. 2005 Sep; 11(6):367-73. PMID: 16103000.
      View in: PubMed
    113. Reed T, Plassman BL, Tanner CM, Dick DM, Rinehart SA, Nichols WC. Verification of self-report of zygosity determined via DNA testing in a subset of the NAS-NRC twin registry 40 years later. Twin Res Hum Genet. 2005 Aug; 8(4):362-7. PMID: 16176721; PMCID: PMC1262657.
    114. Marras C, Lang AE, Oakes D, McDermott MP, Kieburtz K, Shoulson I, Tanner CM, Fahn S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005 Jul 19; 143(2):152-3; author reply 156-8. PMID: 16027463.
      View in: PubMed
    115. Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, Korell M, Langston JW, Ross GW, Tanner CM. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord. 2005 Jun; 20(6):687-93. PMID: 15719425.
      View in: PubMed
    116. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203. PMID: 15668964.
      View in: PubMed
    117. Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18. PMID: 16422311.
      View in: PubMed
    118. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 09; 351(24):2498-508. PMID: 15590952.
      View in: PubMed
    119. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004 Oct; 56(4):532-9. PMID: 15389895.
      View in: PubMed
    120. Tanner CM. PD or not PD? That is the question. Neurology. 2003 Jul 08; 61(1):5-6. PMID: 12847146.
      View in: PubMed
    121. Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov Disord. 2003 Jul; 18(7):758-63. PMID: 12815654.
      View in: PubMed
    122. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 01; 157(11):1015-22. PMID: 12777365.
      View in: PubMed
    123. Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003; 26(7):461-81. PMID: 12735785.
      View in: PubMed
    124. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol. 2003; 91:133-42. PMID: 12442672.
      View in: PubMed
    125. Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, Masaki KH, Blanchette PL, Popper JS, Foley D, Launer L, White LR. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol. 2002 Nov; 59(11):1787-92. PMID: 12433267.
      View in: PubMed
    126. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May; 51(5):604-12. PMID: 12112107.
      View in: PubMed